The use of adenoviruses and herpes viruses in therapy of patients with oncological diseases
Vol 82 No 1 (2019), Theoretical and Experimental Medicine
Vol 82 No 1 (2019)

The use of adenoviruses and herpes viruses in therapy of patients with oncological diseases

Theoretical and Experimental Medicine
https://doi.org/10.35339/msz.2019.82.01.01
Published March 10, 2020
A.Yu. Gavrilov
Kharkiv National Medical University
https://orcid.org/0000-0001-8644-6887
V.V. Polyakova
Kharkiv National Medical University
https://orcid.org/0000-0001-8570-5584
A. Lesnaya
Kharkiv National Medical University
https://orcid.org/0000-0002-6045-1650
PDF (Русский)

Keywords

oncolytic viruses
adenoviruses
herpes viruses
immunotherapy

How to Cite

Gavrilov, A., Polyakova, V., & Lesnaya, A. (2020). The use of adenoviruses and herpes viruses in therapy of patients with oncological diseases. Medicine Today and Tomorrow, 82(1), 4–7. https://doi.org/10.35339/msz.2019.82.01.01
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The pathogenesis mechanisms and theoretical foundations of the interaction of oncolytic viruses with tumor cells are presented. The literature data concerning the most relevant trends in the treatment of people with cancer are analyzed. The possibility of using promising oncolytic viruses, such as adenoviruses and herpes viruses, was considered during treatment, and the optimal concept of combined therapy for cancer patients was developed.

https://doi.org/10.35339/msz.2019.82.01.01
PDF (Русский)

References

Johnson D.B., Puzanov I., Kelley M.C. (2015). Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. Immunotherapy, vol.7 (6), pp. 611–619.

Hawkins L.K., Lemoine N.R., Kirn D. (2002). Oncolytic biotherapy: a novel therapeutic platform. Lancet Oncol., vol. 3 (1), pp. 17–26.

Du T., Han Z., Zhou G., Roizman B. (2015). Patterns of accumulation of miRNAs encoded by herpes simplex virus during productive infection, latency, and on reactivation. Proc. Natl. Acad. Sci. USA, vol. 112, pp. E49–55.

Androlewicz M.J., Cresswell P. (1994). Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity, vol. 1 (1), pp. 7–14.

Yamamoto M., Curiel D.T. (2010). Current issues and future directions of oncolytic adenoviruses. Mol. Ther., vol. 18, pp. 243–250.

Jemal A., Center M.M., DeSantis C., Ward E.M. (2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev., vol. 19, pp. 1893–1907.

Toth K., Wold W.S. (2010). Increasing the efficacy of oncolytic adenovirus vectors. Viruses, vol. 2, pp. 1844–1866, DOI: 10.3390/v2091844.5/.

Hemminki A., Oksanen M., Merisalo-Soikkeli M. (2013). Oncolytic virotherapy trials – letter. Clin. Cancer Res., vol. 19, pp. 4541–4542.

Pol J., Bloy N., Obrist F., Eggermont A., Galon J., Cremer I. et al. (2014). Trial Watch: Oncolytic viruses for cancer therapy. Oncoimmunology, vol. 3, e28694.